Q-omics provides the consensus-scored PCDHB17P profile across patient tissues and cancer cell-line models. PCDHB17P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PCDHB17P is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, PCDHB17P RNA expression shows 10,577 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, KICH, and TGCT as cancer lineages where PCDHB17P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHB17P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHB17P survival associations across molecular data types. PCDHB17P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHB17P RNA expression–survival associations across cancer types. High PCDHB17P expression shows unfavorable associations in STAD, CESC, BLCA, BRCA and LUSC, but favorable associations in OV. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for PCDHB17P RNA expression.
This table summarizes PCDHB17P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHB17P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHB17P shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LUSC, LUAD and KIRC. The KICH box plot shows higher PCDHB17P RNA expression in normal versus tumor tissue (log2 FC = −0.240, t-test p < 0.001).
This table shows molecular features associated with PCDHB17P in patient tissues and cancer cell lines. In patient samples, PCDHB17P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHB17P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
